All these results indicated that MRPL12, MRPL13 and POP1 not only could be designed as prognostic factors for predicting survival probability of patients with breast cancer, but also could be used as potential targets for clinical intervention of breast cancer. This evidence concerns the gene MRPL12 and breast carcinoma.